In February 2026, Hims & Hers Health and Novo Nordisk struck a deal that allows Hims to provide popular weight-loss medications like Wegovy and Ozempic through its telehealth platform. This partnership resolves previous legal issues over compounded semaglutide products and sets the stage for a new direction.
This shift from compounded alternatives to branded drugs means Hims can offer more reliable options while reducing their legal risks. However, it introduces new challenges related to supply and regulations for obesity medications.
For investors, believing in Hims’ vision is crucial. The company aims to establish strong, lasting relationships with consumers in the health tech space. The deal with Novo Nordisk could reshape the company’s growth potential in the weight loss market, but the biggest concern remains regulatory scrutiny around these medications.
Recent guidance from Hims projects sales between $2.7 billion and $2.9 billion for 2026, including income from weight loss, sexual health, lab testing, and cancer screenings. This forecast existed before the partnership with Novo Nordisk and is now central to understanding Hims’ potential.
Looking ahead, some analysts predict Hims could reach $3.3 billion in revenue by 2028, which would require significant annual growth. A few optimistic forecasts even suggest revenues could hit $4.1 billion, but these projections come with their own uncertainties—especially concerning regulatory risk related to lifestyle medications.
Furthermore, user sentiment on social media highlights a mix of optimism and caution. Many users express excitement about accessible weight-loss solutions but voice concerns over the safety and availability of such medications. This chatter reflects a broader trend of increased interest in telehealth services, especially post-pandemic.
For those curious about the health tech market, Hims & Hers represents a significant player aiming to simplify healthcare access. As more companies, like Hims, venture into the telehealth and wellness space, keeping an eye on regulatory developments and consumer feedback will be vital.
You can read more about Hims & Hers Health to get a deeper understanding of its potential in this evolving landscape.
Source link
